SGLT-2 Inhibitors in Heart Failure: Putting the Evidence Into Practice
Published: 27 August 2021
-
Views:
8485
-
Likes:
7
-
Views:
8485
-
Likes:
7
Overview
Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Andrew Coats (Monash University, Australia and University of Warwick, UK) and Prof Giuseppe Rosano (St George's, University of London, UK) discuss the implications for treatment strategies.
This three-part series provides comprehensive update on some of the most important developments in HFrEF management including addressing key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF, when and how to initiate SGLT-2 inhibitors, and making evidence-based choices in the selection of SGLT-2 inhibitor.
Learning Objectives
- Recall the latest recommendations and levels of evidence supporting the use of SGLT-2 inhibitors in heart failure (HF)
- Consider the impact of delaying the adoption of all guideline-directed foundational therapies in existing HF
- Make an evidence-based choice when selecting an SGLT-2 inhibitor in HF
Target Audience
- Heart failure specialists
- Cardiologists
- Referring physicians
- Allied health professionals
More from this programme
Part 1
Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?
Part 2
When and How to Initiate SGLT-2 Inhibitors in HFrEF
Part 3
Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
Prof Rosano's areas of expertise include heart failure, cardiac metabolism, cardiovascular pharmacology and pharmacotherapy, heart disease in women and cardiovascular effects of sex hormones. He has a specific interest in chronic coronary syndromes and in angina with normal coronary arteries.
Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian…